Within this dataset, ST6GAL1 is 6.3 -fold upregulated in the ‘metastatic’ subgroup compared to the ‘non-metastatic’ sub-group, suggesting upregulation of the ST6GAL1 gene in patients with primary prostate cancer presenting with metastatic biology (n = 20, unpaired t test, p = 0.024) (Supplementary Fig. S1a). This evidence concerns the gene ST6GAL1 and prostate cancer.